Daily Bio News Summary — 2026-09-11: Takeda leadership shakeup, Novartis investor revolt, and FDA's evolving regulatory stance
Today's harvest covers Takeda's R&D chief retirement, Novartis facing investor pressure after M&A misfires, FDA's regulatory flexibility on psychedelics, Samsung Biologics' manufacturing deals, and new clinical developments across the biopharma landscape.
Today’s biopharma harvest brings 34 articles from 8 sources, with the heaviest coverage from Fierce Pharma, Fierce Biotech, and BioSpace. Leadership transitions dominate the news cycle, with Takeda’s long-serving R&D chief Andy Plump announcing his retirement and Novartis facing a board overhaul call from activist investors.
Leadership and Corporate Strategy
Takeda’s R&D leadership is in flux. Andy Plump, who has led the company’s research efforts for years, announced his retirement effective next June (Fierce Biotech, BioSpace, Endpoints News). The departure comes after major pipeline reorganizations at the company. Meanwhile, Novartis is under pressure from investors calling for board changes after a series of costly M&A setbacks and R&D flops (Fierce Pharma, BioSpace). The company also faces scrutiny over its triple asset stumble that dragged peers down.
FDA Regulatory Activity
The FDA continues to signal regulatory flexibility, with a notable focus on psychedelics assessment (Endpoints News). The agency’s new oncology chief has set priorities in a first interview (Fierce Pharma). In clearance news, Emboline received 510(k) clearance for its Emboliner embolic protection system (PR Newswire FDA), and Seismic Pharmaceuticals enrolled its first patient in a Phase 3 trial of istaroxime for cardiogenic shock (PR Newswire FDA).
Manufacturing and Business Development
Samsung Biologics continues its deal-making streak, inking a $262M manufacturing deal with a European pharma company (BioSpace, Fierce Pharma). Lonza is investing in US plant expansion while CordenPharma scales injectables (Fierce Pharma). In fundraising, Alzheon outlines plans for a major round despite a Phase 3 miss for its Alzheimer’s drug (Endpoints News).
Clinical and Scientific Developments
Roivant’s pulmonary hypertension drug showed strong Phase 2 data, described as “blowout” results (BioSpace). Biohaven’s epilepsy drug suffered an FDA hold just days after a $350M deal (Fierce Biotech). In research news, a STAT News article explores how platinum-based chemotherapy in childhood causes mutations that age the liver. Another STAT piece examines why two promising heart drugs flopped and what’s next.
Industry Trends
Singapore is launching a biotech-focused Boston hub with a glitzy event (Fierce Biotech). Scientists are beginning a boycott of the American Diabetes Association (Fierce Biotech). AbbVie is eyeing Qulipta expansion after a menstrual migraine win (Fierce Pharma). NICE has rebuffed Gilead’s twice-yearly PrEP option (Fierce Pharma).
Reading Order
- Takeda’s R&D chief retirement and its implications
- Novartis investor revolt and board overhaul demands
- FDA’s regulatory flexibility on psychedelics
- Roivant’s “blowout” Phase 2 data
- Samsung Biologics’ $262M manufacturing deal
Sources: BioSpace, Fierce Pharma, Fierce Biotech, Endpoints News, STAT News, PR Newswire FDA, MedCity News, Pharmaphorum